Paroxetine 20mg 30 tablets — Made in Cyprus — Free Delivery

Brand: Medochemie
Product Code: Paroxetine
Availability: In Stock

$42.41

Add to Cart

Description

Indications

Treatment of major depressive disorder.

Treatment of symptoms and prevention of recurrence of obsessive-compulsive disorder.

Treatment of symptoms and prevention of relapses of panic disorder with or without concomitant agoraphobia.

Treatment of social phobias / social anxiety conditions.

Treatment of symptoms and prevention of recurrence of generalized anxiety disorder.

Treatment of post-traumatic stress disorder.

Contraindications

Hypersensitivity to paroxetine or any other component of the preparation.

Paroxetine should not be administered simultaneously with MAO (MAO) inhibitors, including linezolid, an antibiotic that is a reversible non-selective inhibitor of MAO and methylthionine chloride (methylene blue), and earlier than 2 weeks after stopping treatment with MAO inhibitors (see section "Interaction with other preparations means and other types of interactions”). MAO inhibitors should not be used earlier than 2 weeks after stopping treatment with paroxetine.

The preparation should not be used in combination with thioridazine, because, like other preparations that suppress the hepatic enzyme CYP450 2D6, Paroxetine can increase the level of thioridazine (see Section "Interaction with other medicinal products and other forms of interaction"). The use of thioridazine may cause QT prolongation with associated severe ventricular arrhythmia (eg, torsades de pointes) and sudden death.

Paroxetine should not be administered in combination with pimozide (see Section "Interaction with other medicinal products and other forms of interaction").

Compound

active ingredient: paroxetine;

1 tablet contains paroxetine hydrochloride 22.22 mg equivalent to paroxetine 20 mg

Excipients: microcrystalline cellulose, calcium hydrogen phosphate dihydrate, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate.

Method of application and dose.

The preparation is intended for oral use, it is recommended to take 1 time per day - in the morning with meals. The tablet should be swallowed without chewing.

As with other psychiatric agents, abrupt discontinuation of the preparation should be avoided.

Major depressive disorder. The recommended daily dose is 20 mg. Usually the condition begins to improve after a week, but sometimes the improvement is not visible until the second week of treatment.

As with all antidepressant preparations, the dose must be carefully selected individually during the first 3-4 weeks of treatment, and then adjusted depending on the clinical manifestations.

For the treatment of some patients with an insufficient response to a dosage of 20 mg, an increase in dose may be required. This should be done gradually, increasing the dose by 10 mg (up to a maximum of 50 mg per day), depending on the clinical effectiveness of the treatment. The course of treatment of patients with depression should be long enough, at least 6 months, to ensure the elimination of symptoms.

Obsessive-compulsive disorder. The recommended daily dose is 40 mg. Treatment should begin with a dose of 20 mg per day, and then gradually increase it by 10 mg per day to the recommended dose. In some patients, improvement is observed only when using the maximum dose of 60 mg per day. The course of treatment for obsessive-compulsive disorder should be long enough to ensure the elimination of symptoms. This period can last several months or even longer.

panic disorder. The recommended dose is 40 mg per day. Treatment should begin with a dose of 10 mg per day, then increase it by 10 mg weekly, depending on the clinical effect. In some patients, improvement is observed only when using the maximum dose of 60 mg per day.

To reduce the risk of increased symptoms of panic disorder, often observed at the beginning of treatment for this disease, it is recommended to start treatment with a low dose of the preparation.

Social anxiety disorders/social phobias. The recommended dose is 20 mg per day. For some patients, the dose can be gradually increased by 10 mg per day - depending on the clinical effect of the treatment, up to 50 mg per day. The interval between dose increases should be at least 1 week. Long-term use of the preparation should be reviewed periodically.

Generalized anxiety disorder. The recommended dose is 20 mg per day. In case of insufficient effectiveness when using 20 mg, the dose can be gradually increased by 10 mg per day, depending on the clinical effect, up to 50 mg per day. Long-term use of the preparation should be reviewed periodically.

Post-traumatic stress disorder. The recommended dose is 20 mg per day. In case of insufficient effectiveness when using 20 mg, the dose can be gradually increased by 10 mg per day, depending on the clinical effect, up to 50 mg per day. Long-term use of the preparation should be reviewed periodically.

Cancellation of paroxetine.

As with other psychiatric preparations, abrupt discontinuation of the preparation should be avoided. During clinical studies, a dose reduction regimen of the preparation was used, which included reducing the daily dose by 10 mg per day with an interval of 1 week. After reaching the dosing regimen of 20 mg, patients took the preparation at this dose for another week before completely canceling it. In the event of the appearance of severe symptoms during a dose reduction or after discontinuation of treatment, it is necessary to decide whether to resume treatment at the previous dose. Later, you can continue to reduce the dose, but at a slower pace.

Elderly patients. Treatment begins with the usual initial dose for adults, which can then be gradually increased to 40 mg per day. There have been cases of an increase in the concentration of paroxetine in the blood plasma of elderly patients, but the range of concentrations in this group of patients coincides with the corresponding range in younger patients.

Children. Paroxetine is not indicated for the treatment of children.

Renal and liver failure. In patients with severe renal insufficiency (creatinine clearance less than 30 ml / min) or hepatic insufficiency, an increase in the concentration of paroxetine in the blood plasma is observed. Therefore, for such patients, the dose should be reduced to the lower end of the dosing range.

0 reviews

There are no reviews for this product.